Search results for "Cytotoxic"

showing 10 items of 1673 documents

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

2019

ABSTRACT HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8+ T cells. HPV-positive TC-1 and C3 tumors of immunized mice are heavily infiltrated with ac…

0301 basic medicinelcsh:Immunologic diseases. AllergyT cellImmunologyhpv16-positive malignancieslcsh:RC254-282t cell memoryhpv 16 rna-lpx03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunology and AllergyCytotoxic T cellMedicineOriginal Researchbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structureOncologyImmunization030220 oncology & carcinogenesisCancer researchCancer vaccinebusinesscancer vaccinelcsh:RC581-607CD8e7OncoImmunology
researchProduct

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

2019

TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a novel synthetic agonist with exquisite specificity for TLR7. We found that intravenously administered SC1 mediates systemic release of type I interferon, but not of proinflammatory cytokines such as TNFα and IL6, and results in activation of circulating immune cells. Tumors of SC1-treated mice have brisk immune cell infiltrates and are polarized towards a Th1 type signature. Intratumoral CD8(+) T cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsImmunologytype i interferonlcsh:RC254-282Proinflammatory cytokinetlr7 ligand03 medical and health sciences0302 clinical medicineImmune systemInterferonmedicineImmunology and AllergyCytotoxic T cellOriginal ResearchToll-like receptorcancer immunotherapybusiness.industryTLR7Acquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbusinesslcsh:RC581-607CD8medicine.drugOncoImmunology
researchProduct

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo

2018

Cancer-associated mutations, mostly single nucleotide variations, can act as neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsmedicine.medical_treatmentImmunologyBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyAntigenmedicineImmunology and AllergyCytotoxic T cellneoepitopescancer immunotherapycd8+ t cell cytotoxicityT-cell receptorImmunotherapyTumor-Derivedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpointt cell priming030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchlcsh:RC581-607CD8OncoImmunology
researchProduct

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

2017

γδ T cells usually infiltrate many different types of cancer, but it is unclear whether they inhibit or promote tumor progression. Moreover, properties of tumor-infiltrating γδ T cells and those in the corresponding normal tissue remain largely unknown. Here we have studied features of γδ T cells in colorectal cancer, normal colon tissue and peripheral blood, and correlated their levels with clinicopathologic hallmarks. Flow cytometry and transcriptome analyses showed that the tumor comprised a highly variable rate of TILs (5–90%) and 4% γδ T cells on average, with the majority expressing Vδ1. Most Vδ1 and Vδ2 T cells showed a predominant effector memory phenotype and had reduced production…

0301 basic medicinelcsh:Immunologic diseases. Allergycolon cancer; DFS; IFN-g; TILs; gd T cells; Immunology and Allergy; Immunology; OncologyColorectal cancerImmunologyBiologyifn-γDFStilslcsh:RC254-28203 medical and health sciencesIFN-gmedicineCytotoxic T cellImmunology and AllergyOriginal ResearchSettore MED/04 - Patologia Generaleγδ t cellsCancergd T cellTILmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologycolon cancerOncologyTumor progressionImmunologylcsh:RC581-607Oncoimmunology
researchProduct

Anticancer properties of 5Z-(4- fuorobenzylidene)-2-(4- hydroxyphenylamino)-thiazol-4-one

2019

Abstract4-thiazolidinones, which are privileged structures in medicinal chemistry, comprise the well-known class of heterocycles and are a source of new drug-like compounds. Undoubtedly, the 5-bulky-substituted-2,4-thiazolidinediones - a class of antihyperglycemic glitazones, which are peroxisome proliferator-activated receptor gamma (PPARγ) agonists, are the most described group among them. As there are various chemically distinct 4-thiazolidinones, different subtypes have been selected for studies; however, their main pharmacological profiles are similar. The aim of this study was to evaluate the anticancer activity of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one (Les-2…

0301 basic medicinelcsh:MedicineAntineoplastic AgentsApoptosisDrug developmentArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumorLactate dehydrogenaseHumansViability assaylcsh:ScienceCytotoxicityReceptorchemistry.chemical_classificationReactive oxygen speciesMultidisciplinaryDose-Response Relationship DrugL-Lactate DehydrogenaseMolecular medicineCaspase 3lcsh:RMetabolismPeroxisomeThiazoles030104 developmental biologychemistryBiochemistryA549 CellsPreclinical researchCell culturelcsh:QCaco-2 CellsReactive Oxygen Species030217 neurology & neurosurgeryScientific Reports
researchProduct

The swinholide biosynthesis gene cluster from a terrestrial cyanobacterium, Nostoc sp. strain UHCC 0450

2017

ABSTRACT Swinholides are 42-carbon ring polyketides with a 2-fold axis of symmetry. They are potent cytotoxins that disrupt the actin cytoskeleton. Swinholides were discovered from the marine sponge Theonella sp. and were long suspected to be produced by symbiotic bacteria. Misakinolide, a structural variant of swinholide, was recently demonstrated to be the product of a symbiotic heterotrophic proteobacterium. Here, we report the production of swinholide A by an axenic strain of the terrestrial cyanobacterium Nostoc sp. strain UHCC 0450. We located the 85-kb trans -AT polyketide synthase (PKS) swinholide biosynthesis gene cluster from a draft genome of Nostoc sp. UHCC 0450. The swinholide …

0301 basic medicinemarine environmentterrestrial environmentDIVERSITYcyanobacteria01 natural sciencesApplied Microbiology and BiotechnologyBiochemistryTrans-AT PKSMARINE CYANOBACTERIAGene clusterEnvironmental MicrobiologyskeletonSPONGE THEONELLA-SWINHOEISpotlightAxenicNostocgene transfertoxinSwinholide1183 Plant biology microbiology virologyPhylogenychemistry.chemical_classificationEcologybiologyAnabaena sp.ChemistryAnabaenaHorizontal gene transferKetonesbacteriumenzyme activityphylogeneticsINSIGHTSBiochemistryMultigene Familyhorizontal gene transferscytophycinScandium compoundspolyketidesBiotechnologyNostoctrans-AT PKSScytophycinNONRIBOSOMAL PEPTIDEBiosynthesisCyanobacteriaswinholideCYTOTOXIC DIMERIC MACROLIDES03 medical and health sciencesPolyketideBacterial ProteinsNonribosomal peptidecyanobacteriumPolyketide synthaseProteobacteriaCONGENERSCandidatus Entotheonellabovine spongiform encephalopathygeneNostoc sp.Bacteriacatalysis010405 organic chemistryProteinsSequence Analysis DNAbiology.organism_classificationActin cytoskeletonAnabaenaEVOLUTION"Candidatus Entotheonella"0104 chemical sciencesenzymeNATURAL-PRODUCT DISCOVERY030104 developmental biologyGenesPolyketidesbiology.proteingene expressionbacteria“Candidatus Entotheonella”Theonella sp.Marine ToxinsPolyketide SynthasesFood Sciencecatalyst
researchProduct

Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA

2017

Jay Amin Hydroxamic Acid (JAHA; N8-ferrocenylN1-hydroxy-octanediamide) is a ferrocene-containing analogue of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA). JAHA’s cytotoxic activity on MDA-MB231 triple negative breast cancer (TNBC) cells at 72 h has been previously demonstrated with an IC50 of 8.45 M. JAHA’s lethal effect was found linked to perturbations of cell cycle, mitochondrial activity, signal transduction and autophagy mechanisms. In order to glean novel insights on how MDA-MB231 breast cancer cells respond to the cytotoxic effect induced by JAHA, and to compare the biological effect with the related compound SAHA, we have employed a combination of…

0301 basic medicinemedicine.drug_classAntineoplastic AgentsTriple Negative Breast NeoplasmsBiologyHydroxamic AcidsToxicologyStructure-Activity Relationship03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansCytotoxic T cellFerrous CompoundsSettore BIO/06 - Anatomia Comparata E Citologiaskin and connective tissue diseasesVorinostatTriple-negative breast cancerVorinostatDose-Response Relationship DrugHistone deacetylase inhibitorComputational BiologyGeneral MedicineTriple Negative Breast NeoplasmsCell cycleHistone Deacetylase InhibitorsSettore BIO/18 - Genetica030104 developmental biologyBiochemistryCell culture030220 oncology & carcinogenesisCancer researchHistone deacetylaseJAHA Comet assay MDA-MB231 Histone Deacetylase InhibitorsDrug Screening Assays Antitumormedicine.drug
researchProduct

Prospecting for cytotoxic and antiprotozoal 4-aryl-4H-chromenes and 10-aryldihydropyrano[2,3-f]chromenes.

2018

Different studies reported that genetic predisposition or metabolic dysfunction are the risk factors for cancer. Infectious parasitic diseases were listed among factors that predispose to cancer. Because of the resemblance between the life cycle of cancer cells and some parasites, this study aimed to prepare pyran derivatives with cytotoxic and antiprotozoal potencies. Therefore, 7 chromenes, 10 pyranocoumarins, and an unexpected intermediate were obtained from a multi-reagent one-pot reaction. These compounds were evaluated for their cytotoxicity on sensitive and resistant leukemia cancer cells lines and against two protozoan parasites, namely Trypanosoma cruzi and Leishmania amazonensis a…

0301 basic medicinemedicine.drug_classAntiparasiticTHP-1 CellsTrypanosoma cruziAntiprotozoal AgentsPharmaceutical ScienceAntineoplastic AgentsApoptosisPharmacology03 medical and health sciencesStructure-Activity RelationshipParasitic Sensitivity TestsDrug DiscoverymedicineTumor Cells CulturedCytotoxic T cellHumansBenzopyransTrypanosoma cruziCytotoxicityAmastigoteCell ProliferationLeishmaniabiologyDose-Response Relationship DrugMolecular StructureChemistryCancerCell Cycle Checkpointsbiology.organism_classificationmedicine.disease030104 developmental biologyCancer cellAntiprotozoalDrug Screening Assays AntitumorArchiv der Pharmazie
researchProduct

Managing cancer patients during the COVID-19 pandemic:an ESMO multidisciplinary expert consensus

2020

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed …

0301 basic medicinemedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Settore MED/18 - CHIRURGIA GENERALEPneumonia ViraleducationDiseaseMedical OncologyReal-Time Polymerase Chain ReactionSpecial Article03 medical and health sciencesBetacoronavirus0302 clinical medicineMultidisciplinary approachNeoplasmsPandemicGranulocyte Colony-Stimulating FactorMedicineHumansDisease management (health)PandemicsSocieties Medicalbusiness.industrySARS-CoV-2Expert consensusCOVID-19Disease ManagementcovidHematologyTelemedicineEurope030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicineCancer managementSevere acute respiratory syndrome coronavirusbusinessCoronavirus InfectionsT-Lymphocytes Cytotoxic
researchProduct